Physician profile
Daisy C Cortes
NPI 1215234356
$384,537.03
in general payments reported to CMS, 2019-2025
31 companies · $150K in 2025
The $150K reported for 2025 was more than what 99% of Pediatric Hematology-Oncology providers received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $5,090 · 2021: $46K · 2022: $77K · 2023: $21K · 2024: $70K · 2025: $150K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $153K · Consulting Fee: $58K · Travel and Lodging: $20K · Food and Beverage: $7,259 · Honoraria: $2,400 · Education: $60.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $152,990.89 |
| Consulting Fee | $57,959.00 |
| Travel and Lodging | $20,081.00 |
| Food and Beverage | $7,258.85 |
| Honoraria | $2,400.00 |
| Education | $60.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $208,839.51 | 2019-2025 | Esperoct, Alhemo, Rebinyn |
| Genzyme Corporation | $86,573.78 | 2019-2025 | |
| Genentech USA, INC. | $18,971.72 | 2019-2023 | Hemlibra |
| Bayer Healthcare Pharmaceuticals INC. | $16,830.21 | 2019-2025 | |
| Csl Behring | $15,442.51 | 2020-2025 | Hemgenix, Idelvion |
| Octapharma USA, INC. | $12,407.50 | 2019-2025 | Nuwiq, Wilate - Von Willebrand Factor/Coagulation Factor Viii Complex (Human) |
| Pfizer INC. | $6,819.62 | 2019-2025 | |
| Shire North American Group INC | $5,764.50 | 2019 | |
| Genentech, INC. | $3,568.01 | 2019-2025 | Hemlibra |
| Bio Products Laboratory USA, INC. | $3,201.47 | 2019-2023 | Gammaplex, Coagadex |
| Takeda Pharmaceuticals U.S.A., INC. | $2,451.12 | 2021-2025 | Advate, Adynovate |
| Kedrion Biopharma, INC. | $588.79 | 2024-2025 | Gammaked, Kedrab, Koate |
| Spark Therapeutics, INC. | $452.59 | 2019-2023 | |
| Grifols Shared Services North America, INC. | $355.92 | 2019-2022 | |
| Grifols USA, LLC | $342.65 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $274.86 | 2025 | Pyrukynd |
| Bioverativ Therapeutics INC. | $262.74 | 2019 | |
| Global Blood Therapeutics, INC. | $255.26 | 2021-2022 | |
| Incyte Corporation | $223.98 | 2021 | |
| Chiesi USA, INC. | $192.60 | 2021-2025 | Ferriprox, Kengreal |
| Medexus Pharma, INC. | $149.27 | 2024-2025 | Ixinity |
| Hema Biologics, LLC | $141.69 | 2021-2025 | Sevenfact |
| Biomarin Pharmaceutical INC. | $101.02 | 2021-2025 | Roctavian |
| Astellas Pharma US INC | $99.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $90.13 | 2022 | |
| Rare Disease Therapeutics, INC. | $45.72 | 2025 | Xromi |
| Aptevo Therapeutics INC | $41.73 | 2019-2020 | |
| Kedrion Biopharma INC. | $19.43 | 2019 | |
| Duchesnay USA Incorporated | $15.22 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.48 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daisy Cortes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.